Zydus Cadila To Begin Phase-2 Clinical Trials Of 'ZyCoV-D' Covid-19 Vaccine From 6 August

Drug firm Zydus Cadila on Wednesday (5 August) announced that its plasmid DNA vaccine to prevent COVID-19 — ZyCoV-D — was found to be safe and well tolerated in the phase I clinical trial. The company will now commence phase II clinical trials from 6 August.

The company in a statement said that the doses of the vaccine administered to healthy volunteers in the phase I clinical trial, which began on 15 July, were well tolerated.

“The Phase I dosing to establish the safety of ZyCoV-D is an important milestone,” said Pankaj R Patel, Chairman Zydus Cadila.

“All the subjects in Phase I clinical trial were closely monitored in a clinical pharmacological unit for 24 hours post dosing for safety and for 7 days thereafter and vaccine was found to be very safe," Patel said.

“We now begin the phase II clinical trials and look forward to evaluating the safety and immunogenicity of the vaccine in a larger population,” he added.

The statement came a day after Director General of Indian Council of Medical Research Balram Bhargava said that the DNA vaccine by Zydus Cadila has completed phase I trials and embarked on phase II at 11 sites.

Previously, the vaccine was found to be safe, immunogenic and well tolerated in the pre-clinical toxicity studies. The vaccine was able to elicit a high level of neutralisation of antibodies in animal studies.

The seven day safety study of the vaccine in all the subjects enrolled in the Phase I clinical trial has been endorsed by the independent Data Safety Monitoring Board (DSMB), which has been constituted to oversee the safety aspects of the clinical trial, the company said.

The phase II trial will be evaluating the humoral and cellular immune response for the vaccine candidate in line with the current global clinical trial protocols in general.

With ZyCoV-D, the company has successfully established the DNA vaccine platform in the country using non-replicating and non-integrating plasmid carrying the gene of interest making it very safe.

The plasmid DNA when introduced into the host cells would be translated into the viral protein and will elicit a strong immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance.

Besides this, ICMR chief Balram Bhargava had also said that the inactivated virus vaccine by Bharat Biotech has completed its phase I study at 11 sites and has started its phase II study.

“There is no specific drug or vaccine available yet. The need for the vaccine is great and urgent but there is a dilemma – the pandemic is progressing rapidly and developing the vaccine may take time,” he had said.

According to the ICMR, there are 141 vaccine candidates which are being studied the world over, out of which 26 are in different phases of the clinical trial. Three vaccines are in different phases of clinical testing in India.

(With inputs from IANS)